Has Bryan Johnson confirmed using rapamycin?

Yes. Johnson publicly confirmed rapamycin as part of his Blueprint protocol, typically at 13 mg biweekly. He announced in early 2024 that he discontinued it after biological-age clock data raised concerns about net benefit. The discontinuation was shared on his YouTube channel and social accounts.

Is Bryan Johnson's protocol safe to replicate?

The HealthRX.com Medical Team strongly cautions against replicating Johnson's full protocol without equivalent medical supervision. He employs a team of 30+ physicians and undergoes continuous monitoring. The drug-drug interaction profile of 200+ simultaneous agents has never been studied. Several components (peptides, off-label prescriptions) carry risks that are difficult to quantify outside a supervised setting.

What is acarbose and why does Johnson take it?

Acarbose is an FDA-approved alpha-glucosidase inhibitor for type 2 diabetes. It slows carbohydrate digestion, reducing postprandial glucose spikes. The NIA Interventions Testing Program found it extended median lifespan in male mice by 22%. Johnson uses it as a glucose-management tool within his calorie-restricted diet.

What did Bryan Johnson's rapamycin discontinuation mean for the longevity community?

Johnson's public decision to stop rapamycin based on biological-age clock data was one of the first high-profile examples of a longevity self-experimenter abandoning a cornerstone drug based on personal outcome data. It highlighted the gap between animal lifespan data and individual human response, and reinforced that biological-age clocks remain imperfect surrogate endpoints.

Bryan Johnson and Longevity: The Documented Public Record

Q: What is the clinical evidence for rapamycin in longevity?

Rapamycin extended median lifespan in mice by 9-14% in the NIA Interventions Testing Program. In humans, a rapamycin analog (everolimus) improved immune function in elderly subjects in a small 2014 trial. No completed human randomized controlled trial has tested rapamycin for lifespan extension.

Q: Are the peptides in Johnson's protocol FDA-approved?

No. BPC-157, GHK-Cu, and hexarelin are not FDA-approved for any indication. The FDA has issued warnings about compounded peptide products, citing quality and safety concerns. Human clinical trial data for these peptides is extremely limited.

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Bryan Johnson and Longevity: The Documented Public Record Image: HealthRX.com clinical image

Who Is Bryan Johnson?

Bryan Johnson is a tech entrepreneur who sold his payments company Braintree to PayPal for $800 million in 2013. In 2021, he launched Project Blueprint, a self-described effort to measure and reverse biological aging using a team of 30+ physicians. He has since published granular protocol data, bloodwork panels, organ-by-organ age scores, and MRI results on his website and YouTube channel.

Johnson's "Don't Die" philosophy has become both a movement and a book. He claims to spend roughly $2 million per year on the protocol. That figure, widely reported by outlets including Bloomberg and the BBC, has made him the most visible figure in the consumer longevity space.

The Confirmed Protocol: What Johnson Has Published

Johnson publishes his daily supplement and drug stack in detail. The following interventions are confirmed by his own public disclosures.

Rapamycin (Sirolimus)

Johnson confirmed rapamycin use as part of Blueprint, typically cited at a dose of 13 mg biweekly (a pulsed schedule). Rapamycin is an mTOR inhibitor originally approved as an immunosuppressant for organ transplant recipients. Animal data on rapamycin and lifespan extension is among the strongest in the longevity field: the National Institute on Aging's Interventions Testing Program demonstrated median lifespan increases of 9% in males and 14% in females in genetically heterogeneous mice.

In early 2024, Johnson publicly announced he had discontinued rapamycin. He stated the decision was linked to concerns about his biological-age clock readings, suggesting the drug may not have been producing the net benefit he expected. He shared this on his YouTube channel and social media.

The HealthRX.com Medical Team notes that rapamycin's longevity data in humans remains limited to observational and small-cohort studies. A 2014 trial by Mannick et al., published in Science Translational Medicine, showed that a rapamycin analog (everolimus) improved immune function in elderly subjects at low doses. Extrapolating mouse lifespan data to human dosing is a gap that no completed randomized trial has yet bridged.

Acarbose

Johnson has listed acarbose in his published protocol. Acarbose is an alpha-glucosidase inhibitor approved by the FDA for type 2 diabetes. It slows carbohydrate absorption in the gut, blunting postprandial glucose spikes. The same NIA Interventions Testing Program that validated rapamycin also found acarbose extended median lifespan in male mice by 22%, with a smaller effect in females.

For a non-diabetic individual, acarbose's primary longevity rationale is glucose-spike reduction. Side effects are predominantly gastrointestinal: bloating, flatulence, and diarrhea, particularly during the first weeks of use. The HealthRX.com Medical Team observes that Johnson's extremely controlled diet (low glycemic, calorie-restricted) likely minimizes both the glucose-lowering magnitude and GI side effects of acarbose.

NAD+ Precursors (NMN)

Johnson has confirmed daily nicotinamide mononucleotide (NMN) supplementation. NMN is a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in hundreds of metabolic reactions. NAD+ levels decline with age, and restoring them is a central hypothesis of the longevity-supplement market.

A 2022 randomized controlled trial published in Science showed that NMN supplementation (250 mg/day) increased blood NAD+ levels in middle-aged and older adults. Clinical endpoints like lifespan extension remain unproven. The HealthRX.com Medical Team emphasizes that NAD+ repletion is biologically plausible but remains in the "promising preclinical, early clinical" category.

Testosterone and Hormone Optimization

Johnson has published his testosterone protocol, which includes monitoring and optimizing free and total testosterone levels. His approach sits within a broader hormone-optimization framework that he describes as targeting the hormone profile of an 18-year-old. He has shared specific testosterone blood values publicly.

Testosterone replacement in men is FDA-approved for diagnosed hypogonadism. The 2023 TRAVERSE trial, published in The New England Journal of Medicine, provided reassurance on cardiovascular safety in hypogonadal men aged 45 to 80, though it was not designed to assess longevity endpoints. Johnson has not disclosed a hypogonadism diagnosis; his stated goal is optimization rather than replacement.

Peptides: BPC-157, GHK-Cu, and Others

Johnson's published protocol includes several peptides. BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in gastric juice. Animal studies suggest tissue-repair and anti-inflammatory properties, but no completed human randomized controlled trials exist for BPC-157.

GHK-Cu is a copper-binding tripeptide with published evidence for wound healing and collagen synthesis in cell and animal models. Johnson has also referenced hexarelin, a growth-hormone secretagogue peptide, in protocol documentation.

The HealthRX.com Medical Team flags that most peptides in Johnson's stack lack rigorous human trial data. The FDA has not approved BPC-157, GHK-Cu, or hexarelin for any indication. In 2023, the FDA issued warnings about compounded peptide products, citing quality and safety concerns.

The 200+ Daily Interventions

Johnson reports taking over 100 pills daily, spanning vitamins, minerals, prescription drugs, and experimental compounds. Beyond the agents listed above, his published stack includes metformin (another diabetes drug studied for longevity), lithium orotate (microdosed), DHEA, and numerous antioxidants. The full list is published on his Blueprint website and updated periodically.

The sheer number of simultaneous interventions creates a significant pharmacological problem: drug-drug interactions at this scale are essentially unstudied. No clinical trial has ever tested a protocol of this complexity. The HealthRX.com Medical Team considers this the single most important limitation of Johnson's experiment. Positive or negative outcomes cannot be attributed to any individual agent when 200+ variables change simultaneously.

What Remains Speculated

Some media reports have attributed additional interventions to Johnson that he has not confirmed in his published protocol. These include specific dosages of certain growth-hormone-related therapies and some IV-infusion protocols shown in video content but not formally listed in his Blueprint documentation. The HealthRX.com Medical Team treats anything not in Johnson's published, version-controlled protocol as speculated, and we recommend readers do the same.

The HealthRX.com Medical Team Take

Johnson's experiment is valuable for one primary reason: transparency. He publishes biomarker data that most longevity clinics keep proprietary. His public discontinuation of rapamycin was a genuinely useful data point for the longevity community, demonstrating that even committed self-experimenters should re-evaluate interventions when outcomes disappoint.

The risks are real. Polypharmacy at this scale introduces unpredictable interactions. Several agents in his stack (rapamycin, acarbose, testosterone) carry known side-effect profiles documented by the FDA, and the peptides carry the additional risk of unregulated compounding. Johnson's wealth allows for continuous physician monitoring that the average person cannot replicate, making his protocol impractical and potentially dangerous to imitate without equivalent medical infrastructure.

The science behind individual components of his stack ranges from strong (rapamycin's mouse data, acarbose's ITP results) to speculative (most peptides, many supplements). No single human trial supports the combined use of these agents for lifespan extension.

At a glance

Status: Bryan Johnson has publicly confirmed his longevity protocol through Project Blueprint, publishing detailed daily regimens and biomarker data since 2021
Key confirmed drugs: Rapamycin (discontinued 2024), acarbose, NMN, testosterone optimization, BPC-157, GHK-Cu, hexarelin, metformin
Strongest evidence: Rapamycin and acarbose both showed lifespan extension in the NIA Interventions Testing Program in mice
Biggest limitation: 200+ simultaneous interventions make it impossible to attribute outcomes to any single agent
Regulatory note: Several peptides in the protocol (BPC-157, GHK-Cu) lack FDA approval for any indication and face compounding-quality concerns
Cost barrier: Johnson reports spending roughly $2 million per year, with continuous physician monitoring that is not replicable for most people

Frequently asked questions

›

References

Harrison, D. E., et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature 460 (2009): 392-395. https://pubmed.ncbi.nlm.nih.gov/19587680/
Mannick, J. B., et al. "mTOR inhibition improves immune function in the elderly." Science Translational Medicine 6.268 (2014). https://pubmed.ncbi.nlm.nih.gov/25540326/
Harrison, D. E., et al. "Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males." Aging Cell 13.2 (2014): 273-282. https://pubmed.ncbi.nlm.nih.gov/24591560/
Yoshino, M., et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science 372.6547 (2022): 1224-1229. https://pubmed.ncbi.nlm.nih.gov/36040339/
Lincoff, A. M., et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." New England Journal of Medicine 389 (2023): 107-117. https://www.nejm.org/doi/full/10.1056/NEJMoa2215025
Seiwerth, S., et al. "BPC 157's effect on healing." Journal of Physiology and Pharmacology 69.6 (2018). https://pubmed.ncbi.nlm.nih.gov/29300396/
FDA. "Acarbose Label." https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020482s025lbl.pdf
FDA. "Certain Bulk Drug Substances Used in Compounding." https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-used-compounding-under-section-503b-federal-food-drug-and-cosmetic-act
FDA. "Drug Safety Communication: Testosterone Products." https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due